Eli Lilly's Massive Revenue Surge Sparks Major Wall Street Upgrades
New York, Sunday, 17 May 2026.
Fueled by a staggering 56 percent surge in first-quarter revenue, analysts are aggressively raising Eli Lilly’s price targets as the company’s global dominance in weight-loss treatments accelerates.
A Blockbuster First Quarter and Expanding Global Reach
Eli Lilly and Company (NYSE: LLY) reported formidable first-quarter results for 2026, generating $19.8 billion in revenue, which represents a 55.55% increase compared to the same period the previous year [6]. On April 30, 2026, the company announced earnings of $8.55 per share, surpassing Wall Street estimates by $1.58 [5]. This financial outperformance prompted Chief Executive Officer David Ricks to declare that the year had commenced with exceptional strength, leading the pharmaceutical titan to raise its full-year revenue guidance by $2 billion [2].
Global Market Expansion and Mounjaro Growth
The driving force behind this revenue expansion is the company’s commanding presence in the global incretin and obesity treatment markets. In the first quarter of 2026, Mounjaro’s revenue outside the United States reached $4.4 billion, a 33.333% increase from the $3.3 billion recorded in the fourth quarter of 2025 [2]. International adoption has been rapid; Mounjaro is now available in more than 55 countries and captures approximately 53% of the international incretin market, with market share exceeding expectations.